Schedule 13G ownership disclosure
Aimmune Therapeutics, Inc.
Security class unavailable · CUSIP: 00900T107
Event date: 2015-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,324,117
- Percent of class
- 5.5000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000903423-16-000777
- Form type
- SC 13G
- Filer
- Aimmune Therapeutics, Inc.
- CIK
- CIK 1631650
- Filed
- Jan 29, 2016
- Reporting period
- Dec 31, 2015
- Description
- Schedule 13G beneficial ownership